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ABSTRACT
Objective: The study objective was to assess the utility of placental leucine aminopeptidase (P-LAP) marker for the prediction of delivery in patients 
presented with threatened preterm labor (TPL).
Methods: This study included 90 pregnant women with gestational age from (28-36+6) weeks; 45 of them who presented with preterm uterine 
contractions were considered as the study group which was further subdivided into three subgroups according to gestational age 28–31+6 weeks, 32–
33+6 weeks, and 34–36+6 weeks. The other 45 pregnant women who presented to the hospital for regular antenatal care visit at comparable gestational 
age to the study group were considered as the control group. Hence, this study aimed to assess the serum level of P-LAP in both groups and compare 
it between those delivered preterm from term to assess its applicability as a predictor of preterm labor.
Results: Serum level of P-LAP in pregnant women presented with TPL was found to be significantly lower in those delivered preterm (p<0.001), 
compared to those continued to term and control group especially in gestational ages ≥32 weeks, while the study found P-LAP level to be statistically 
insignificant in gestational age <32 weeks (p=0.052). The cutoff point for P-LAP serum level was = 21 (IU/ml) that below it,  the pregnant women 
with TPL most probably deliver before 37 weeks of gestation with Sensitivity (85.7%) Specificity (90.3%), Positive predictive value (80.0%) Negative 
predictive (93.3%).
Conclusion: The serum level of P-LAP was lower in women delivered preterm than those delivered at term, so it can be used as one of the markers for 
the prediction of preterm delivery, especially at gestational age >32 weeks.
Keywords: Placental leucine aminopeptidase, Pregnant women, Preterm birth.
INTRODUCTION
Term pregnancy is defined as gestational age from 37+0 to 41+6 weeks, 
whereas preterm birth (PTB) is defined as delivery of a baby before 
37 completed weeks of pregnancy [1]. The onset of labor may be 
diagnosed by documented uterine contractions (at least once in every 
10 min) and documented cervical change with an estimated cervical 
length of <1 cm or cervical dilation of >2 cm. Threatened preterm 
labor (TPL) is diagnosed when there are documented regular uterine 
contractions but no evidence of cervical change [2,3]. The prevalence 
of PTB varies among different ethnic groups. Globally, 35% of 
neonatal deaths are due to prematurity [4]. PTB is the single-largest 
cause of death among children under the age of 5 years [5]. With 
improvement of fertility treatment, more cases with TPL are seen due 
to the higher incidence of multiple gestation [6]. The pathophysiology 
of PTB is unknown; however, various causes including activation of 
the maternal/fetal (hypothalamic–pituitary axis), inflammation or 
infection, decidual hemorrhage, and abnormal uterine distension [7-9]. 
Unexplained spontaneous PTB (SPTB) is the main cause of preterm 
labor [10]. Nowadays, evidence of genetic factor thought to affect 
the duration of gestation [11]. For early detection of preterm labor, 
various screening tools have been used including monitoring of uterine 
activity, assessment of cervical length by ultrasound, cervical fetal 
fibronectin measurement, and the presence of bacterial vaginosis in 
early pregnancy [12,13]. Placental leucine aminopeptidase (P-LAP), 
which is called oxytocinase or insulin-regulated aminopeptidase, is 
a glycosylated aminopeptidase Type II integral membrane protein 
of 1024 amino acids, which belongs to Zn+2 [14]. P-LAP is mostly 
synthesized from placental syncytiotrophoblasts during pregnancy. It 
degrades several peptide hormones which are produced by the fetus 
such as oxytocin, vasopressin, and angiotensin II [15] Aminopeptidases 
are large molecules that do not cross the placental barrier; hence they 
act as antiuterotonic and antihypertensive agents by degrading these 
peptides [16]. P-LAP activity level in maternal serum increases with 
the gestational age to reach a maximum  near term and reaching a 
plateau just prior to the onset of labour. P-LAP is useful for predicting 
the time of labor onset, especially in preterm labor [17,18]. Studies on 
oxytocinase’s role in regulating blood pressure and uterine contraction 
during pregnancy have been carried out focusing on the possibility to 
use it in the treatment of preterm labor and pre-eclampsia [19-21].
Aim of study
The objective of this study is to evaluate the accuracy of serum level of 
P-LAP\oxytocinase in pregnant women who presented with TPL as a 
predictor of preterm delivery.
METHODS
Study design
This study was a prospective case–control study.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i4.32053
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This study was conducted at the Obstetrics and Gynaecology Department of Al-Yarmouk Teaching Hospital in the period from March 2017 to June
 2018.
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Setting
This study was conducted at the Obstetrical Department of Al-Yarmouk 
Teaching Hospital in Baghdad city and was carried out from March 2017 
to June 2018 after approval by the supervising committee of Arabic 
Board of Obstetrics and Gynaecology. Verbal consent was obtained 
from all the patients. Forty-five patients who attended our hospital for 
routine antenatal care visit with comparable gestational age and had no 
uterine contractions were included in the study and were considered 
as control group.
Inclusion criteria
Pregnant with Singleton alive fetus, Gestational age 28- 36+6 weeks 
determined by Last menstrual period and/or reliable obstetrical 
ultrasound at first trimester were eligible to be enrolled in the control 
group. For study group: Women with regular uterine contraction 




• Chronic and gestational hypertension




Those patients who fulfilled the inclusion and exclusion criteria and 
agreed to participate in the study were subjected to the following:
1. Clinical history including:
• History of present illness
• Past obstetrical history (e.g., gravida, parity, history of preterm 
labor)
• Past gynecological history (e.g., genital infections)
• Drug history
• Pastsurgical (e.g., cervical conization)
• Social history.
2. Clinical examination including:
a. General examination which includes body mass index and vital 
signs.
b. Obstetrical examination: Abdominal examination by Leopold’s 
maneuvers and speculum examination for the study group.
3. Laboratory investigations for all patients:
a. 10 mL of venous blood was taken from all patients and sent for 
the following investigations:
 1. Complete blood count
 2. Random blood sugar
 3. Liver function tests
 4. 5 mL of blood was collected and used for serum P-LAP level 
test which was allowed to clot for 2 h at room temperature and 
then centrifuged for 20 min at approximately 1000 × g. The 
supernatant was collected and stored at −20°C until the time 
of transport to the private laboratory where the level of P-LAP 
was assayed and the results were expressed as IU\mL. The 
lower detection limit of the assay was 5 IU\mL. The kit used was 
human (leucyl-cystinyl aminopeptidase) kit based on sandwich 
enzyme-linked immunosorbent assay technology, manufactured 
by My BioSource\USA.
b. Midstream general urine examination done for all patients to 
exclude urinary tract infection and proteinuria.
4. Management of TPL for study group patients:
 Patients of the study group were admitted to the Obstetrical 
Department at Al-Yarmouk Teaching Hospital and were given the 
following tocolytic agents according to our hospital policy:
1. Ca++ channel blockers: Nefidipine (Adalat) capsule (10 mg) 
per oral as loading dose (one capsule) and then assessment of 
uterine contractions after 30 min; if not subsided, the dose was 
repeated and then reassessment of contraction was also made 
after 30 min from the second dose if uterine contractions did 
not subside and one other capsule was given as the last dose. If 
contraction subsided, the patient was kept on maintenance dose 
as one capsule every 8 h.
2. Progestational agents: Dydrogesterone (Duphaston) film-coated 
tablets (10 mg) per oral and progesterone (Cyclogest) 400 mg 
vaginal pessaries. If contractions had not subsided and delivery 
proceeded, the patient had been referred to the labor room or 
operation theater according to obstetrical indication.
5. Follow-up:
 After treatment was given to the study group, if patients’ uterine 
contractions subsided, then the patients were hospitalized for further 
48 h, then discharged home, and further followed up till the time of 
delivery for risk of preterm labor. Patients in the control group also 
were followed up to the time of delivery for risk of preterm labor.
Statistical analysis
The data were analyzed using Statistical Package for the Social Sciences 
(SPSS, ver. 22, IBM-Armonk, New York, USA, 2017). The categorical data 
were presented by numbers and percentages. Pearson’s Chi-square 
test was used to test the association between categorical variables. 
Continuous variables were presented by mean, standard deviations, 
and ranges. Independent t-test and analysis of variance were used to 
analyze the differences of continuous variables according to the study 
group. The validity criteria of P-LAP level in detecting preterm labor 
among women with premature uterine contraction were tested by 
receiver operating characteristic curve method. p value was considered 
statistically significant at 0.05 level.
RESULTS
A total of 90 pregnant women (45 preterms and 45 controls) were 
included in the study; their age ranged from 21 to 34 years, their 
parity was from primigravida up to 5 parities, their gestational ages 
at presentation were from 28 to 36+6 weeks, control group collected at 
comparable gestational age(28 – 36+6)  to study group (Table 1).
Fig. 1 shows pregnancy outcome in the study group as 66.6% of them 
were delivered term and 33.4% were delivered preterm.
As shown in Table 2, the maternal age was significantly associated 
with PTB (p=0.027), whereas the parity association with PTB was not 
significant (p=0.94).
As shown in Table 3, the gestational age at presentation among the 
study groups was not significantly associated with being term or 
preterm delivery (p=0.982), whereas the gestational age at delivery 
among the study groups was significantly associated with term or 
preterm delivery (p<0.001), and there was no significant association 
between the mode of delivery and being term or preterm (P = 0.897).
Table 4 shows that there was no significant association between 
fetal gender and being delivered term or preterm (p=0.684), but 
birth weights were significantly lower in preterm delivered babies 
(p<0.001). Apgar score at 1 minute and at 5 minutes was significantly 
lower in preterm delivered neonates (P-value <0.001) for Apgar score 
at 1 minute and (P-value 0.001) for 5 minute.
As shown in Table 5, there was a significant difference in serum 
P-LAP level among the study groups of different gestational ages 
at presentation between those delivered term and those delivered 
preterm, especially with gestational age groups ≥32 weeks (p<0.001). 
There was no significant difference in the level of serum P-LAP 
(p=0.152) at gestational age ≤32 weeks.
Table 6 shows that the sensitivity and negative predictive value (NPV) 
of P-LAP to determine preterm delivery among women with TPL 
according to gestational age at presentation was 100%.
In Fig. 2, the cut-off point for P-LAP level was = 21 (IU/mL) that below 
it the pregnant women with threatened preterm labour (TPL) most 
probably deliver before 37 weeks of gestation; the test sensitivity was 
85.7%, specificity was 90.3%, positive predictive value (PPV) was 
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Table 1: Demographic characteristics of the control and study groups
Variables Control group (n=45) Study group (n=45) p value
Mean±SD Mean±SD
Maternal age (years) 26±5 31±5 0.006*
Parity 2±2 3±2 0.728
Gestational age at presentation (weeks) 33.4±1.9 33.3±2 0.898
Gestational age at delivery (weeks) 39±1.1 36.4±1.6 <0.001*
Gestational age groups at presentation (weeks) n (%) n (%)
28–31+6 7 (15.6) 7 (15.6) 1
32–33+6 23 (51.1) 23 (51.1)
34–36+6 15 (33.3) 15 (33.3)
Total 45 (100) 45 (100)
SD: Standard deviation, *Significant at 0.05 by independent t-test
Table 2: Comparison of women’s age and parity among the study groups with the term and preterm deliveries
Variables Controls, n=45 Study group p value
Term delivery, n=30 Preterm delivery, n=15
Mean±SD Mean±SD Mean±SD
Maternal age 26±5s 29±6 32±5 0.027*
Parity 2±2 3±2 3±2 0.94
SD: Standard deviation, *Significant at 0.05 by ANOVA, s:Significantly different group, ANOVA: Analysis of variance
Table 3: Gestational age at presentation among the study groups with regard to term and preterm deliveries, and the association with 
the mode of delivery
Variables Controls, n=45 Study group p value
Term delivery, n=30 Preterm delivery, n=15
Mean±SD Mean±SD Mean±SD
Gestational age at presentation (weeks) 33.4±1.9 33.3±1.9 33.4±2.2 0.982
Gestational age at delivery (weeks) 39±1.1 37.5±0.9* 36±1.3s <0.001*
Groups of gestational age at presentation (weeks) n (%) n (%) n (%)
28–31+6 7 (15.6) 5 (16.7) 2 (13.3) 0.977
32–33+6 23 (51.1) 16 (53.3) 7 (46.7)
34–36+6 15 (33.3) 9 (30) 6 (40)
Mode of delivery n (%) n (%) n (%)
Vaginal delivery 31 (68.9) 22 (73.3) 11 (73.3) 0.897
Cesarean section 14 (31.1) 8 (26.7) 4 (26.7)
SD: Standard deviation, *Significant at 0.05 by ANOVA, s: significantly different group, ANOVA: Analysis of variance
Table 4: Parameters of the delivered neonates among the study and control groups
Variables Controls, n=45 Study group p value
Term, n=30 Preterm, n=15
Gender of the baby    
Male 19 (42.2) 15 (50) 8 (53.3) 0.684
Female 26 (57.8) 15 (50) 7 (46.7)
Birth weight (g) 3230±408 3356±497 2203±600s <0.001*
Apgar score at 1 min 7±1 8±1 6±1s <0.001*
Apgar score at 5 min 8±1 8±1 7±1s 0.001*
SD: Standard deviation, *Significant at 0.05 by ANOVA, s: Significantly different group, ANOVA: Analysis of variance
80.0%, NPV was 93.3%, and accuracy was 88.9%. The dotted line in 
Fig. 2, represents the cutoff point for serum P-LAP level, which is equal 
to 21 IU/mL.
DISCUSSION
PTB is a major cause of neonatal mortality, which is estimated to 
be at least 50% of all neonatal deaths, with the highest rates of 
health-care costs due to hospitalization of women with preterm labor 
and the expenses of long-term care of PTB [22]. preterm birth rates 
have increased all over world even in most industrialised countries 
during the past two decades ,so efforts to lower the rate of this major 
complication of pregnancy needs to be one of the highest priorities in 
contemporary health care [23]. Prediction of PTB considered one of 
most important steps in prevention of PTB and its complications [24].
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Numerous biochemical markers, for example, fetal fibronectin, cervical 
interleukin-6, and α-fetoprotein have been investigated for the prediction 
of PTB, which may also explain the mechanism of SPTB [25]. In this study, 
we investigated P-LAP level in women presented with TPL and followed 
them up to the time of delivery to assess the difference in P-LAP level 
between those who continue till term and those who delivered preterm.
In the current study, maternal age was significantly different in preterm 
delivered group (p=0.006). Higher incidence of preterm labor was found 
Fig. 1: Study group, n=90
Fig. 2: Relation of placental leucine aminopeptidase level with 
gestational age at presentation according to outcome, n = 90
births among women presenting with threatened preterm labor
Table 5: Comparison of P-LAP levels among the study and control groups according to gestational age at presentation
Serum P-LAP level (IU\mL)
Gestational age at presentation (weeks) Controls, n=45 Term, n=30 Preterm, n=15 p value
Mean±SD Mean±SD Mean±SD
28–31+6 31.1±29.9 25.6±23.8 12.1±11.8 0.152
32–33+6 57.4±22.9 51.4±24.8 13.4±2.4s <0.001*
34–36+6 79.6±16s 63.2±26s 12.3±9.2s <0.001*
Overall 66±23.7 56.7±25.5 13.7±6.9s <0.001*
SD: Standard deviation, *Significant at 0.05 by ANOVA, s: significantly different group, P-LAP: Placental leucine aminopeptidase
Fig. 4: Receiver operating characteristic curve for the detection 
of placental leucine aminopeptidase validity in the detection 
of preterm births among women presenting with threatened 
preterm labor at gestational age of 28–31+6 weeks
Fig. 5: Receiver operating characteristic curve for the detection 
of placental leucine aminopeptidase validity in the detection 
of preterm births among women presenting with threatened 
preterm labor at gestational age of 32–33+6 weeks
Fig. 3: Receiver operating characteristic curve for the detection of 
placental leucine aminopeptidase validity in the detection of preterm 
305
Asian J Pharm Clin Res, Vol 12, Issue 4, 2019, 301-307
 Hassan et al. 
in patients older than 31 years, a finding which is in agreement with 
other studies like Waldenström et al.’s study, 2016 [26]. Iin his study 
advance maternal age(women aged 35 years and older ) was associated 
with an increased risk of PTB, and Florent Fuchs et al study 2018  [27], 
confounded that advanced maternal age (>40 years old) was associated 
with higher risk of preterm labor. The difference in maternal age of the 
current study and that of others might have attributed to the social 
differences of our community (e.g., lower age of marriage) from that of 
others. While Goisis et al.’s study, 2017 [28], disagree with this finding, 
in which comparison between maternal ages ( 25–29) years with 
maternal ages of (35–39) years and (≥40) years were associated with 
percentage increases of 1.1 points (95% confidence intervals[CI]:0.8, 
1.4) and 2.2 points (95% CI: 1.4, 2.9), respectively, in the probability 
Table 6: Validity criteria of P‑LAP to determine preterm delivery among women with TPL, according to gestational age at presentation
Groups according to 
gestational age (weeks)
P-LAP (IU/mL) AUC* Sensitivity Specificity PPV** NPV*** Accuracy
28–31+6 27 0.9 100.0 80.0 66.7 100.0 85.7
32–33+686 16 1 100.0 100.0 100.0 100.0 100.0
34–36+6 31 0.981 100.0 88.9 85.7 100.0 93.3
*AUC: Area under curve, **PPV: Positive predictive value, ***NPV: Negative predictive value, P-LAP: Placental leucine aminopeptidase, TPL: Threatened preterm labor
of PTB, while in within-family models, the relationship between 
advanced maternal age and low birth weight or PTB is statistically and 
substantively negligible. Thus, the study states that advanced maternal 
age is not independently associated with the risk of low birth weight or 
preterm delivery among mothers who have had at least two live births.
With regard to parity, in the current study, there was no significant 
difference between maternal parity and birth of preterm, and this was 
in agreement with Lisonkova et al.’s study, 2010 [29], which concluded 
that older women were at elevated risk of PTB and neonatal intensive 
care unit admission regardless of parity. The study claimed that parity 
modifies the effect of maternal age on the incidence of PTB, as older 
primiparas were at higher risk of PTB than older multiparas.
While the current study disagreed with Shaikh et al study 2011 [30]
and Kozuki et al study 2013 [31]. Their studies confound that PTB was 
associated with nulliparous women (especially maternal age<18 years 
of age) and higher parity ≥3 (especially maternal age ≥35) mothers.
The distribution of neonatal gestational age for those who delivered 
preterm was predominantly among 32–33+6 weeks of gestational age, 
and this finding was in disagreement with that of Kuzniewicz et al.’s 
study, 2017 [32], which was a retrospective cohort study of singleton 
pregnancies that involved 365,897 pregnant women presented with 
TPL. Preterm delivery occurred in 85% of admitted cases within 48 h 
of admission. Nearly 96% of the delivered cases were at gestational 
age ≥34 weeks, 67% at 31–33 weeks, and 51.9% at <31 weeks. The 
current study results showed that 13.33% of preterm deliveries were 
at 28–31+6 weeks of gestation, while 46.66% were at 32–33+6 weeks and 
40% at 34–36+6 weeks.
The current study showed no significant association between gender of 
baby and being delivered preterm, a finding which is in agreement with 
that of Teoh et al.’s study, 2018 [33], which was a cohort prospective 
study carried out on 2505 pregnant women, who were at high risk of 
preterm delivery, divided according to gender into two groups, and 
were observed till the time of delivery. The difference in the incidence 
of preterm delivery between female and male newborns was found to 
be nonsignificant with a relative risk [RR] of 1.07 (p=0.383).
Peelen et al.’s study, 2016 [34], and Brettell et al.’s study, 2008 [35], 
considered male gender as a risk factor for preterm labor. Peelen 
et al.’s study comprised 1,736,615 singleton deliveries between 25 and 
42+6 weeks of gestation, in which male gender was found to be associated 
with higher incidence of spontaneous preterm delivery, especially at 
27–31 weeks of gestation (RR 1.5), while the incidence was equal for 
both genders in indicated preterm delivery. Whereas in Brettell et al.’s 
study, a retrospective study conducted on 75,725 deliveries in a UK 
teaching hospital, 4003 women were delivered preterm, male delivery 
was more frequent in spontaneous but not indicated preterm delivery 
(OR 1.30, 95% CI 1.19–1.42).
Regarding Apgar score for newborn babies, the current study showed 
a significant difference (p<0.001) as it was lower in those delivered 
preterm, and this agreed with the studies of Svenvik et al., 2015 [36], 
and Lee et al., 2010 [37].
Svenvik et al. conducted a retrospective registry cohort study involving 
21,126 births, analysis of risk factors in new-borns with Apgar Score 
Fig. 6: Receiver operating characteristic curve for the detection 
of placental leucine aminopeptidase validity in the detection 
of preterm labor among women presenting with threatened 
preterm labor at gestational age of 34–36+6 weeks
Fig. 7: Extra comparison between three groups of gestational ages 
included
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<7 revealed preterm delivery is the most common factor, in (32-36+6) 
gestational weeks.
However, Lee et al cohort study included 690,933 live births their 
gestational age range 24-36+6 weeks, results were showed that Apgar 
score distributed according to the gestational age at delivery and higher 
proportions of low Apgar scores at 5 minutes found with younger 
gestational age. Current study showed that serum P-LAP level in 
pregnants who delivered preterm at (32-33+6) and(34-36+6) weeks of 
gestation was significantly lower than those delivered term in both the 
study and in control groups , P-value(<0.001), this agreed with H. Kozaki 
et al. study 2001 [38] , while in the gestational age group (28-31+6)
weeks study showed non-significant difference  in serum P-LAP level 
with p-value (0.152) and this disagree with H. Kozaki et al. study 2001.
Kozaki et al.’s [38] study assessed the maternal serum P-LAP activity in 61 
women who presented with preterm labor and followed them until the 
time of delivery. This study was preceded by a prospective study by the 
same authors which involved 1536 healthy pregnant women who had 
no associated medical diseases and delivered at term and determined 
normal reference values for P-LAP activity in different gestational ages 
of pregnancy. Results of serum P-LAP activity in those presented with 
preterm labor showed that, if it was below the 10th centile, there was a 
greater proportion of preterm delivery (p=0.0085). Moreover, the risk 
to deliver preterm increased to 2.3 folds. The sensitivity, specificity, 
PPV, and NPV were 29%, 97%, 89%, and 62%, respectively. The study 
concluded that maternal serum P-LAP activity decreases in cases of 
spontaneous preterm delivery, and can be used as a possible predicting 
marker for preterm labor because of its low sensitivity and hence the 
authors recommended to use other markers along with it, especially in 
cases of chorioamnitis.
In the current study, the sensitivity, specificity, PPV, NPV were 85.7%, 
90.3%, 80.0%, and 93.3%, respectively.
The study results showed 85.7% sensitivity of P-LAP test, so P-LAP can 
be used as one of the biomarkers in the prediction of PTB. The higher 
sensitivity found in our study compared to that by Kozaki et al.’s [38]. 
study might be probably due to high selective criteria for inclusion in 
our study.
The high specificity of P-LAP (90.3%) proposes that there is a direct 
role of P-LAP\oxytocinase in the mechanism of PTB.
CONCLUSION
• P-LAP serum level was found to be lower in preterm delivered 
women than those delivered term, especially at gestational age group 
≥32 weeks.
• The study showed increased risk of PTB with advanced maternal 
age (>31 years old), but there was no relation with the parity of 
mothers.
• Neonatal gender had no effect on the outcome of TPL.
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